Organization | Vermont Oxford Network

Vermont Oxford Network Report issue

Foundation Phase 3

Organization Overview

First Clinical Trial

2003

NCT00244101

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2008

Timeline

NOW

Now

Alternative names

Director of Clinical Trials, Vermont Oxford Network

Active Ingredients

Drugs in Phase 3 Trials (3)

bifidobacterium infantis (1 trial)

lactobacillus rhamnosus (1 trial)

surfactant (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Birth Weight (Phase 3)

Body Weight (Phase 3)

Respiratory Distress Syndrome (Phase 3)

Respiratory Distress Syndrome, Newborn (Phase 3)

Syndrome (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 2
# of Trial APIs: 3